News Allergy Therapeutics suffers phase 3 birch allergy jab trial... UK-based Allergy Therapeutics has suffered a setback after phase 3 results from the B301 trial of its latest birch allergy product failed to reduce symptoms.
Views & Analysis UK biotech round-up: Autolus joins CAR-T race, Horizon’s new... Three small, innovative firms demonstrate the diversity and promise of the UK bioscience sector.
News Former Seagen CEO Siegall pops up at new biotech Siegall resigned from Seagen last year amid claims of domestic abuse, though was not charged.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK